** Shares of Cognition Therapeutics CGTX.O rise 76.7% to 81 cents premarket

** Drug developer says its experimental oral drug, CT1812, met the main goal of safety and tolerability in a mid-stage study

** The study enrolled 130 patients with mild-to-moderate dementia with Lewy bodies - a type of dementia that affects thinking, movement, behavior, and mood

** Co says "patients treated with CT1812 for six months experienced improvement in behavioral, functional, cognitive and movement measures compared to placebo"

** Adds, "there was a marked reduction in caregiver distress, which suggests a positive impact on the day-to-day lives of those receiving the drug"

** Says detailed data will be presented at a medical conference in January 2025

** Says expediting plans to advance CT1812 into late-stage trials

** Up to last close, stock down 75.4% YTD

(Reporting by Sneha S K in Bengaluru)

((Sneha.SK@thomsonreuters.com))